Breaking News Instant updates and real-time market news.

AAPL

Apple

$178.00

-1.55 (-0.86%)

, AMZN

Amazon.com

$1,681.42

7.6 (0.45%)

12:52
11/30/18
11/30
12:52
11/30/18
12:52

Amazon says Apple Music to be available on Echo devices later this month

Amazon (AMZN) announced in a blog post that Apple Music (AAPL) will be available on Echo devices beginning the week of December 17. Apple Music subscribers will be able to enjoy Apple Music's 50M songs on Echo devices. Customers will be able to ask Alexa to play their favorite songs, artists, and albums-or any of the playlists made by Apple Music's editors from around the world, covering many activities and moods. Customers will also be able to ask Alexa to stream expert-made radio stations centered on popular genres like Hip-Hop, decades like the 80s, and even music from around the world, like K-Pop. Just ask Alexa to play Beats 1 to hear Apple Music's global livestream including in-depth artist interviews- all completely ad-free. Simply enable the Apple Music skill in the Alexa app and link your account to start listening, Amazon said.

AAPL

Apple

$178.00

-1.55 (-0.86%)

AMZN

Amazon.com

$1,681.42

7.6 (0.45%)

  • 04

    Dec

  • 04

    Dec

AAPL Apple
$178.00

-1.55 (-0.86%)

11/30/18
MSCO
11/30/18
NO CHANGE
Target $253
MSCO
Overweight
Apple 'worst case' for tariffs could lower FY19 EPS 10%-20%, says Morgan Stanley
After President Donald Trump alluded to the potential for tariffs being placed on Apple iPhones and laptops imported from China in a recent interview with the Wall Street Journal, Morgan Stanley analyst Katy Huberty said that Apple relocating its final assembly base out of China, and even Asia more broadly, is "largely inconceivable" given that China is one of the only countries that can provide such a large and low-cost labor force with the expertise in manufacturing and tooling that is required to assemble over 300M devices annually. She believes the most realistic scenario is to keep the supply chain largely intact in the near-term and either pass the tariff cost to the consumer or absorb the cost of the tariff internally. If Apple were to pass the cost off to consumers, Huberty believes it could face significant demand and unit headwinds. However, if Apple were to fully absorb the full 10-25% tariff, the cost of the tariffs could ultimately impact FY19 EPS by $1 in the case of a 10% tariff and about $2.50 in the case of a 25% tariff, Huberty tells investors. Consensus for Apple's FY19 EPS is currently $13.45. Huberty has an Overweight rating and $253 price target on Apple shares.
11/30/18
JPMS
11/30/18
NO CHANGE
Target $266
JPMS
Overweight
Apple recent selloff presents opportunity for investors, says JPMorgan
The 19% decline in Apple shares since the company's fiscal Q4 earnings report appears to have already priced in an "overly bearish scenario" of a greater than 10% iPhone volume decline in fiscal 2019, the impact of multi-year volume declines on Services, and potential new tariffs, JPMorgan analyst Samik Chatterjee tells investors in a research note. However, based on the analyst's checks, he does not find a need to tweak his iPhone volume forecasts for fiscal 2019 and 2020 further at this time. He believes the current valuation "sets a fairly low bar" on Apple shares. Chatterjee keeps an Overweight rating on Apple with a $266 price target.
11/29/18
SBSH
11/29/18
NO CHANGE
SBSH
Citi consumer electronics survey positive for Corning, negative for GoPro
Citi surveyed 60 retail and electronics stores in the U.S. during mid-November to inquire about promotions, sell-through, and preferences for various consumer electronics products, analyst Jim Suva tells investors in a research note. The analyst calls television the "clear winner," followed by video game accessories and wireless speakers. The results point to continued size migration to 50 inch-plus TVs and strong elasticity of demand for price promotions, says Suva. He believes this benefits Corning (GLW). The analyst also finds the video gaming accessories trends as positive for Logitech (LOGI). Fitness trackers and smartwatch trends are neutral for Fitbit (FIT) and positive for Apple (AAPL), while digital camera trends negative for GoPro (GPRO), adds Suva.
11/28/18
WEDB
11/28/18
NO CHANGE
Target $275
WEDB
Outperform
Apple price target lowered to $275 from $310 at Wedbush
Wedbush analyst Daniel Ives lowered his price target for Apple to $275 from $310 to reflect his reduced estimates and softer near-term iPhone data points. While the recent selloff in the shares has been a "painful one that is hard to stomach" for tech investors, he strongly believes that the valuation on the name at current levels and further monetization of its 750M-plus active iPhone installed base through future upgrades and a $50B-plus services revenue stream speaks to his bullish thesis on Apple for the coming years which remains unchanged. Nonetheless, Ives ultimately believes Apple will need to seriously contemplate pricing changes and/or design changes with the next cycle of iPhones slated for the fall of 2019 to drive a surge of upgrade activity that has moved out of FY19 and into FY20 as well as significantly invest in its content/services strategy over the next 12-18 months to drive more growth initiatives. He reiterates an Outperform rating on the shares.
AMZN Amazon.com
$1,681.42

7.6 (0.45%)

11/30/18
RBCM
11/30/18
NO CHANGE
Target $200
RBCM
Outperform
VMware price target raised to $200 from $180 at RBC Capital
RBC Capital analyst Matthew Hedberg raised his price target on VMWare (VMW) to $200 and kept his Outperform rating after its "strong" Q3 results and initial FY20 outlook that calls for revenue growth of 12% - better than the consensus of 8%. The analyst believes that the results highlight the "impressive acceleration at scale and increasing role in driving customers' hybrid cloud initiatives", also raising his FY19 EPS view by 6c to $6.20 and FY20 by 5c to $6.73. Hedberg is also positive on VMWare's growing relationship with Amazon's (AMZN) AWS and the "potential for additional capital allocation beyond the current buyback", along with its "attractive valuation" and "under-owned" market status.
11/30/18
JEFF
11/30/18
UPGRADE
Target $47
JEFF
Buy
UDR, Inc. upgraded to Buy from Hold at Jefferies
Jefferies analyst Omotayo Okusanya upgraded UDR, Inc. (UDR) to Buy and raised his price target for the shares to $47 from $42. The company's above average net operating income growth and development pipeline position it to be one of the best funds from operations growth stories in 2019, Okusanya tells investors in a research note. Further, the analyst sees UDR as one of the biggest beneficiaries from Amazon's (AMZN) new headquarters. He notes the company owns one asset in New York with a commute under 30 minutes to the new Long Island City headquarters and three assets within a three-mile radius to the new headquarters in Arlington, Virginia.
11/29/18
JMPS
11/29/18
NO CHANGE
Target $2050
JMPS
Outperform
Amazon event showed AWS expanding its lead, says JMP Securities
After attending Amazon's AWS re:Invent conference, JMP Securities analyst Ronald Josey said he is more confident on AWS, citing the event's increased attendance, increased streaming audience and the multiple new products and services that were announced this week. Josey, who said AWS continues to expand its lead in the Cloud market, keeps an Outperform rating and $2,050 price target on Amazon shares.
11/28/18
KEYB
11/28/18
NO CHANGE
KEYB
KeyBanc sees Amazon entry having little near-term impact on HCIT space
The announcement that Amazon.com (AMZN) is developing Software-as-a-Service analytical tools for the U.S. healthcare industry called Amazon Comprehend Medical will likely bring a "lot of noise, but little real, near-term financial impact" to the publicly traded Healthcare Technology and Services space, KeyBanc analyst Donald Hooker tells investors in a research note. He believes companies potentially most relevant to Amazon's announcement include Allscripts Healthcare Solutions (MDRX), Cerner (CERN), Evolent Health (EVH), Inovalon Holdings (INOV), IQVIA Holdings (IQV), Medidata Solutions (MDSO), PRA Health Sciences (PRAH), Premier (PINC), and Teladoc Health (TDOC). Hooker argues that any potential success by mega-tech companies, such as Amazon, to develop useful SaaS analytical tools "could actually empower traditional HCIT and biopharma outsourcing companies." Further, he sees a number of "unique barriers" for "big data" solutions in clinical decision support and population health management.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

09:34
11/13/19
11/13
09:34
11/13/19
09:34
General news
Powell says current monetary policy stance 'likely to remain appropriate' »

Federal Reserve Chairman…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

09:33
11/13/19
11/13
09:33
11/13/19
09:33
General news
Powell says 'noteworthy risks' to baseline economic outlook remain »

Federal Reserve Chairman…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$89.00

6.3 (7.62%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Recommendations
Tyson Foods analyst commentary  »

Tyson Foods price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPI

eXp World Holdings

$9.96

0.13 (1.32%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Conference/Events
eXp World Holdings management to meet with DA Davidson »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

TRPX

Therapix Biosciences

$1.41

-0.16 (-10.19%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Hot Stocks
Therapix Biosciences says Phase IIa study of THX-110 met primary endpoint »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLM

Martin Marietta

$255.29

-0.7 (-0.27%)

09:31
11/13/19
11/13
09:31
11/13/19
09:31
Conference/Events
House Science, Space & Technology Committee to hold a hearing »

The Subcommittee on Space…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

EEFT

Euronet

$149.96

1.99 (1.34%)

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Conference/Events
Euronet management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

DG

Dollar General

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Recommendations
Dollar General analyst commentary  »

Dollar General Q3 comp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Dec

BGNE

BeiGene

$196.20

4.5 (2.35%)

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Downgrade
BeiGene rating change  »

BeiGene downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 27

    Feb

DEO

Diageo

$157.94

-1.87 (-1.17%)

09:29
11/13/19
11/13
09:29
11/13/19
09:29
Conference/Events
Diageo management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

DBD

Diebold

$8.10

0.025 (0.31%)

09:28
11/13/19
11/13
09:28
11/13/19
09:28
Conference/Events
Diebold management to meet with DA Davidson »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CBPX

Continental Building

$35.76

3.73 (11.65%)

, GMS

GMS Inc.

$30.73

0.21 (0.69%)

09:27
11/13/19
11/13
09:27
11/13/19
09:27
Recommendations
Continental Building, GMS Inc., Foundation Building Materials analyst commentary  »

Continental Building…

CBPX

Continental Building

$35.76

3.73 (11.65%)

GMS

GMS Inc.

$30.73

0.21 (0.69%)

FBM

Foundation Building Materials

$21.20

0.2 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CRLBF

Cresco Labs

$0.00

(0.00%)

09:27
11/13/19
11/13
09:27
11/13/19
09:27
Conference/Events
Cresco Labs management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CNI

Canadian National

$93.08

-0.485 (-0.52%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Conference/Events
Canadian National management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 21

    Nov

  • 22

    Nov

BRTX

BioRestorative Therapies

$0.00

(0.00%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Conference/Events
BioRestorative Therapies to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TLRY

Tilray

$21.57

-0.4 (-1.82%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Recommendations
Tilray analyst commentary  »

Tilray price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
11/13/19
11/13
09:25
11/13/19
09:25
General news
Fed Chair Powell goes to Capitol Hill for his JEC testimony »

Fed Chair Powell goes to…

EL

Estee Lauder

$187.89

0.63 (0.34%)

09:24
11/13/19
11/13
09:24
11/13/19
09:24
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 06

    Feb

BWEN

Broadwind Energy

$1.53

(0.00%)

09:24
11/13/19
11/13
09:24
11/13/19
09:24
Conference/Events
Broadwind Energy management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

BLDR

Builders FirstSource

$24.75

0.4 (1.64%)

09:22
11/13/19
11/13
09:22
11/13/19
09:22
Conference/Events
Builders FirstSource management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 05

    Dec

NVFY

Nova Lifestyle

$0.54

(0.00%)

09:21
11/13/19
11/13
09:21
11/13/19
09:21
Earnings
Nova Lifestyle reports Q3 revenue $9.3M vs. $16.7M last year »

Tawny Lam, Chairperson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMN

AMN Healthcare

$60.42

0.53 (0.88%)

09:20
11/13/19
11/13
09:20
11/13/19
09:20
Conference/Events
AMN Healthcare management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

PHOT

GrowLife

$0.00

(0.00%)

09:20
11/13/19
11/13
09:20
11/13/19
09:20
Earnings
GrowLife reports Q3 revenue $2.3M vs. $1M last year »

GrowLife CEO Marco Hegyi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$28.32

-0.45 (-1.56%)

09:19
11/13/19
11/13
09:19
11/13/19
09:19
Conference/Events
Aimmune management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

NLTX

Neoleukin Therapeutics

$3.00

0.035 (1.18%)

09:19
11/13/19
11/13
09:19
11/13/19
09:19
Hot Stocks
Neoleukin Therapeutics expects cash to fund operations through 2021 »

Cash and cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.